blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4022062

EP4022062 - NEUROFILAMENT LIGHT CHAIN (NFL) AS A BIOMARKER FOR TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.06.2022
Database last updated on 30.09.2024
FormerThe international publication has been made
Status updated on  05.03.2021
Formerunknown
Status updated on  19.09.2020
Most recent event   Tooltip27.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Henri. A. Termeer Square
Cambridge, MA 02142 / US
[2022/27]
Inventor(s)01 / TICAU, Simina
675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142 / US
02 / NIOI, Paul
675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142 / US
03 / SRIDHARAN, Gautham, Vivek
675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142 / US
04 / TSOUR, Shira
675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142 / US
 [2022/27]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2022/27]
Application number, filing date20768839.128.08.2020
[2022/27]
WO2020US48509
Priority number, dateUS201962894237P30.08.2019         Original published format: US 201962894237 P
US201962925623P24.10.2019         Original published format: US 201962925623 P
US202063044163P25.06.2020         Original published format: US 202063044163 P
[2022/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021041884
Date:04.03.2021
Language:EN
[2021/09]
Type: A1 Application with search report 
No.:EP4022062
Date:06.07.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 04.03.2021 takes the place of the publication of the European patent application.
[2022/27]
Search report(s)International search report - published on:EP04.03.2021
ClassificationIPC:C12N15/113, G01N33/68, A61K31/713
[2022/27]
CPC:
C12N15/113 (EP,US); A61K31/423 (EP); A61K31/603 (EP);
A61K31/713 (EP); A61K45/06 (EP); A61P9/00 (US);
G01N33/68 (US); G01N33/6896 (EP); C12N2310/11 (EP);
C12N2310/14 (EP,US); C12N2320/31 (EP); G01N2333/4709 (EP);
G01N2800/28 (EP); G01N2800/32 (EP); G01N2800/52 (US) (-)
C-Set:
A61K31/423, A61K2300/00 (EP);
A61K31/603, A61K2300/00 (EP);
A61K31/713, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/27]
Extension statesBA21.03.2022
ME21.03.2022
Validation statesKH21.03.2022
MA21.03.2022
MD21.03.2022
TN21.03.2022
TitleGerman:NEUROFILAMENTLICHTKETTE (NFL) ALS BIOMARKER FÜR DIE TRANSTHYRETIN-AMYLOIDOSE-POLYNEUROPATHIE[2022/27]
English:NEUROFILAMENT LIGHT CHAIN (NFL) AS A BIOMARKER FOR TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY[2022/27]
French:CHAÎNE LÉGÈRE NEUROFILAMENTAIRE (NFL) EN TANT QUE BIOMARQUEUR POUR LA POLYNEUROPATHIE LIÉE UNE AMYLOSE À TRANSTHYRÉTINE[2022/27]
Entry into regional phase21.03.2022National basic fee paid 
21.03.2022Designation fee(s) paid 
21.03.2022Examination fee paid 
Examination procedure21.03.2022Amendment by applicant (claims and/or description)
21.03.2022Examination requested  [2022/27]
21.03.2022Date on which the examining division has become responsible
Fees paidRenewal fee
21.03.2022Renewal fee patent year 03
28.08.2023Renewal fee patent year 04
27.08.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2018005967  (PROTHENA THERAPEUTICS LTD [IE], et al) [A] 1-73 * the whole document *;
 [X]WO2018112320  (ALNYLAM PHARMACEUTICALS INC [US], et al) [X] 24-41,56-73 * the whole document *;
 [XY]WO2019060442  (ALNYLAM PHARMACEUTICALS INC [US]) [X] 24-41,56-73 * the whole document * [Y] 1-73;
 [Y]  - ÅSA SANDELIUS ET AL, "Plasma neurofilament light chain concentration in the inherited peripheral neuropathies", NEUROLOGY, US, (20180110), vol. 90, no. 6, doi:10.1212/WNL.0000000000004932, ISSN 0028-3878, pages e518 - e524, XP055746585 [Y] 1-73 * the whole document *

DOI:   http://dx.doi.org/10.1212/WNL.0000000000004932
 [XD]  - MERRILL D. BENSON ET AL, "Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis", NEW ENGLAND JOURNAL OF MEDICINE, US, (20180705), vol. 379, no. 1, doi:10.1056/NEJMoa1716793, ISSN 0028-4793, pages 22 - 31, XP055679307 [XD] 24-41,56-73 * the whole document *

DOI:   http://dx.doi.org/10.1056/NEJMoa1716793
 [A]  - VAN LIEVERLOO, G. ET AL., "Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy", JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, US, (20181201), vol. 23, no. 4, doi:10.1111/jns.12290, ISSN 1085-9489, page 277, XP055676584 [A] 1-73 * the whole document *

DOI:   http://dx.doi.org/10.1111/jns.12290
    [ ] - 2018 Peripheral Nerve Society Annual Meeting 21-25 July, 2018 Baltimore, Maryland
 [AD]  - TERESA COELHO ET AL, "Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis", NEUROLOGY AND THERAPY, (20160219), vol. 5, no. 1, doi:10.1007/s40120-016-0040-x, ISSN 2193-8253, pages 1 - 25, XP055679296 [AD] 1-73 * the whole document *

DOI:   http://dx.doi.org/10.1007/s40120-016-0040-x
 [T]  - MAHIMA KAPOOR ET AL, "Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis", JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, US, (20191014), vol. 24, no. 4, doi:10.1111/jns.12350, ISSN 1085-9489, pages 314 - 319, XP055746563

DOI:   http://dx.doi.org/10.1111/jns.12350
 [T]  - TICAU, S. ET AL., "Neurofilament light chain (NfL) as a potential biomarker in hereditary transthyretin-mediated (hATTR) amyloidosis", JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, US, (20200126), vol. 25, no. S1, doi:10.1111/jns.12361, ISSN 1085-9489, page s13, XP055746545

DOI:   http://dx.doi.org/10.1111/jns.12361
 [T]  - LUIS F. MAIA ET AL, "Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy", AMYLOID, GB, (20200402), vol. 27, no. 2, doi:10.1080/13506129.2019.1708716, ISSN 1350-6129, pages 97 - 102, XP055746560

DOI:   http://dx.doi.org/10.1080/13506129.2019.1708716
by applicantWO2010048228
 WO2011139917
 WO2013075035
 WO2014179627
 WO2015085158
 WO2017023660
    - BENSON et al., N Engl J Med, (20180000), vol. 379, pages 22 - 31
    - COELHO et al., Neurol Ther., (20160000), vol. 5, pages 1 - 25
    - MAURER et al., NEJM, (20180000), vol. 379, pages 1007 - 1016
    - SAID et al., Nature Drug Disc., (20120000), vol. 11, pages 185 - 186
    - COELHO et al., Neurology, (20120000), vol. 79, pages 785 - 792
    - ROSENBLUM et al., Circ Heart Fail., (20180000), vol. 11, page e004769
    - AZORFN CONTESSE et al., Orphanet J Rare Dis., (20150000), vol. 10, no. 1, page 2
    - SOLOMON et al., Circulation, (20190122), vol. 139, no. 4, pages 431 - 443
    - BENSON et al., Am J Cardiol, (20110000), vol. 108, pages 285 - 9
    - ANDO et al., Arch Neurol, (20050000), vol. 62, pages 1057 - 62
    - ANDO et al., Orphanet J Rare Dis., (20130000), vol. 8, page 31
    - DYCK et al., Quantitating overall neuropathic symptoms, impairments, Elsevier, (20050000), pages 1031 - 52
    - DYCK et al., Neurol, (19970000), vol. 49, pages 229 - 39
    - N. SUANPRASERT et al., J Neurol Sci, (20140000), vol. 344, pages 121 - 128
    - DYCK et al., Muscle Nerve, (20030000), vol. 27, no. 2, pages 202 - 10
    - ADAMS et al., BMC Neurology, (20170000), vol. 17, no. 181
    - WITTELES et al., JACC: Heart Failure, (20190000), vol. 7, pages 709 - 716
    - DISANTO et al., Ann Neurol., (20170000), vol. 81, pages 857 - 870
    - LIN et al., Sci Rep., (20180000), vol. 8, page 17368
    - JUDGE et al., Cardiovascular Drugs and Therapy, (20200000), vol. 34, pages 357 - 370
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.